enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One ...

   www.aol.com/finance/fda-approves-checkpoint...

   The recommended commercial dosage of Unloxcyt is 1,200 mg administered as an intravenous infusion over 60 minute FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection ...

3. Cosibelimab - Wikipedia

   en.wikipedia.org/wiki/Cosibelimab

   Cosibelimab, sold under the brand name Unloxcyt, is a monoclonal antibody used for the treatment of cutaneous squamous-cell carcinoma. [1] It is a programmed death ligand-1 (PD-L1) blocking antibody. [ 1 ]

4. PD-1 and PD-L1 inhibitors - Wikipedia

   en.wikipedia.org/wiki/PD-1_and_PD-L1_inhibitors

   Cosibelimab (Unloxcyt) by Checkpoint Therapeutics is a PD-L1 inhibitor developed by Dana Farber, and was approved in the United States in December 2024 for cutaneous squamous cell carcinoma. [ 34 ] Experimental

5. Checkpoint inhibitor - Wikipedia

   en.wikipedia.org/wiki/Checkpoint_inhibitor

   Checkpoint inhibitor therapy is a form of cancer immunotherapy.The therapy targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus.